Scribe Therapeutics Raises $100M Series B Financing to Further Develop 'CRISPR by Design' Platform and Pipeline of Breakthrough Genetic Medicines
|
March 31, 2021
X min read
Scribe’s fully integrated evergreen platform accelerates the development of best-in-class in vivo therapies that treat the underlying cause of disease
|
March 31, 2021
Share on Social
More like this
Media
Another proof point from CIRM-supported research
October 7, 2026
California Institute for Regenerative Medicine
Read Now
Press
Another proof point from CIRM-supported research
October 7, 2026
California Institute for Regenerative Medicine
Read Now
